SX-682 Clinical Trials
5 recruitingDrug
Phase 14Phase 23
Showing 1–5 of 5 trials
Recruiting
Phase 1Phase 2
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Metastatic Colorectal Cancer
National Cancer Institute (NCI)60 enrolled1 locationNCT06149481
Recruiting
Phase 1Phase 2
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
Institute of Cancer Research, United Kingdom78 enrolled4 locationsNCT07002320
Recruiting
Phase 1
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
Myelodysplastic Syndromes
Syntrix Biosystems, Inc.151 enrolled7 locationsNCT04245397
Recruiting
Phase 2
Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Syntrix Biosystems, Inc.53 enrolled6 locationsNCT06228053
Recruiting
Phase 1
A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Pancreatic CancerPancreatic Ductal Adenocarcinoma
University of Rochester20 enrolled1 locationNCT04477343